Syntara Limited (ASX:SNT) Expands Skin Scarring Program with SNT-9465
Program Expansion
Syntara Limited (ASX:SNT) has expanded its skin scarring program with the development of SNT-9465, a next-generation topical anti-fibrotic drug designed for daily use with enhanced tolerability and efficacy.
Clinical Trial Plans
The company will commence a Phase 1a/b clinical trial in Q2 2025, focusing first on safety in healthy volunteers and subsequently on the drug’s effectiveness in improving hypertrophic scars. Results are anticipated in the first half of 2026.
Strategic Partnerships
Syntara has partnered with the Fiona Wood Foundation and the University of Western Australia to conduct an exploratory clinical trial on keloid scarring, providing both financial and technical support.
Executive Comments
CEO Gary Phillips stated, “The knowledge gained from our existing topical skin-scarring compound, in addition to our in-house drug discovery capability, has enabled the rapid refinement of this program and transition to the optimised SNT-9465. With a cost-effective and efficient clinical development strategy, we aim to deliver an IND ready program with evidence supporting safety and efficacy in 2026.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.